Spyre Therapeutics (SYRE) Total Non-Current Liabilities (2015 - 2026)

Spyre Therapeutics' Total Non-Current Liabilities history runs 12 years deep, the most recent figure standing at $36.2 million for Q1 2026.

• Quarterly Total Non-Current Liabilities fell 48.79% year-over-year to $36.2 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $36.2 million (down 48.79% YoY) and the FY2025 annual result came in at $62.5 million, up 15.7% from the prior year.
• Total Non-Current Liabilities was $36.2 million for Q1 2026 at Spyre Therapeutics, down from $62.5 million in the prior quarter.
• Across five years, Total Non-Current Liabilities topped out at $89.2 million in Q2 2023 and bottomed at $20.8 million in Q4 2022.
• A 5-year average of $45.6 million and a median of $43.8 million in 2023 frame the typical range for Total Non-Current Liabilities.
• Annual changes were most pronounced in 2023 — Total Non-Current Liabilities jumped 295.45% — and 2024, when it sank 75.19%.
• Spyre Therapeutics' Total Non-Current Liabilities stood at $20.8 million in 2022, then surged by 53.45% to $32.0 million in 2023, then soared by 69.05% to $54.1 million in 2024, then grew by 15.7% to $62.5 million in 2025, then slumped by 42.13% to $36.2 million in 2026.
• Business Quant data shows SYRE's Total Non-Current Liabilities at $36.2 million in Q1 2026, $62.5 million in Q4 2025, and $46.3 million in Q3 2025.